No Data
Day One Biopharmaceuticals Down Over 17%, On Track for Record Percent Decrease -- Data Talk
JonesTrading Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Cuts Target Price to $30
Express News | Wedbush Reiterates Outperform on Day One Biopharmaceutical, Maintains $32 Price Target
A Quick Look at Today's Ratings for Day One Biopharmaceuticals(DAWN.US), With a Forecast Between $24 to $40
Day One Biopharm Price Target Cut to $36.00/Share From $40.00 by HC Wainwright & Co.
Day One Biopharm Is Maintained at Buy by HC Wainwright & Co.
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}